The Role of Mineralocorticoid Receptors in Vascular Function

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Apparent Mineralocorticoid Excess (AME)

In brief

The purpose of this study is to figure out how decreasing the activity of 11-beta hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta HSD, which is found in the kidneys and blood vessels, is a natural protein that when active helps to keep your blood pressure under control.

Key facts

Study ID

NCT00759525

Run by

Brigham and Women's Hospital

People needed

15

Starts

2002-02-01

Expected to finish

2009-09-01

Last updated by the study team

2016-10-26

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers

You may not qualify if…

• Blood pressure above 140/90
• Abnormal physical finding
• Blood test values for total and LDL cholesterol, CBC, sodium, potassium, creatinine, and glucose laboratories greater 1.5 times normal

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.